Veyvondi Evrópusambandið - íslenska - EMA (European Medicines Agency)

veyvondi

baxalta innovations gmbh - vonicog alfa - von willebrand sjúkdómar - antihemorrhagics - veyvondi er ætlað í fullorðnir (18 ára og eldri) með von willebrand sjúkdómur (vwd), þegar desmópressín (ddavp) meðferð einn er ófullnægjandi eða ekki ætlað til - meðferð blæðing og skurðaðgerð blæðingar - koma í veg skurðaðgerð blæðingar. veyvondi ætti ekki að vera notuð í meðferð með dreyrasýki.

Azacitidine Celgene Evrópusambandið - íslenska - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azasitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Æxlishemjandi lyf - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Drovelis Evrópusambandið - íslenska - EMA (European Medicines Agency)

drovelis

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - hormón kynlíf og stillum kynfæri - oral contraceptive.

PreHevbri Evrópusambandið - íslenska - EMA (European Medicines Agency)

prehevbri

vbi vaccines b.v. - lifrarbólga b yfirborðs mótefnavaka - lifrarbólga b - bóluefni - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Asubtela (Ethinylestradiol/Drospirenon 0,03 mg/3 mg Focus) Filmuhúðuð tafla 3 mg/ 0,03 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

asubtela (ethinylestradiol/drospirenon 0,03 mg/3 mg focus) filmuhúðuð tafla 3 mg/ 0,03 mg

exeltis healthcare s.l. - drospirenonum inn; ethinylestradiolum inn - filmuhúðuð tafla - 3 mg/ 0,03 mg

Copaxone Stungulyf, lausn í áfylltri sprautu 40 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

copaxone stungulyf, lausn í áfylltri sprautu 40 mg/ml

teva gmbh - glatiramer acetat - stungulyf, lausn í áfylltri sprautu - 40 mg/ml

Microgyn Tafla Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

microgyn tafla

bayer ab* - levonorgestrelum inn; ethinylestradiolum inn - tafla

VORTEMYEL Stungulyfsstofn, lausn 3,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vortemyel stungulyfsstofn, lausn 3,5 mg

zentiva k.s.* - bortezomibum inn - stungulyfsstofn, lausn - 3,5 mg

Sitagliptin Zentiva Filmuhúðuð tafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sitagliptin zentiva filmuhúðuð tafla 50 mg

zentiva k.s.* - sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50 mg

Bendamustine Accord Stofn fyrir innrennslisþykkni, lausn 2,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

bendamustine accord stofn fyrir innrennslisþykkni, lausn 2,5 mg/ml

accord healthcare b.v. - bendamustinum hýdróklóríð - stofn fyrir innrennslisþykkni, lausn - 2,5 mg/ml